4 results
To assess sorafenib pharmacokinetics and biodistribution, K-Ras mutational status, tumor uptake and tumor response in NSCLC patients.
The purpose of this study is to ascertain the efficacy, safety, tolerability and pharmacokineticsof LNP023 over a 24-week treatment period compared with rituximab in subjects with MN.
Primary ObjectivesThe primary objectives for this study are as follows:* To evaluate the safety and tolerability of atezolizumab and ipilimumab when administered in combination in patients with advanced or metastatic non-small cell lung cancer (…
To evaluate the dose response relationship of LNP023 on the reduction in proteinuria versus placebo after 90 days of treatment in patients with IgA nephropathy.